TEAD4

Summary

TEAD4 (TEA domain transcription factor 4, HGNC:11717) is a protein-coding gene on chromosome 12p13.33, encoding Transcriptional enhancer factor TEF-3 (Q15561). Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis.

This gene product is a member of the transcriptional enhancer factor (TEF) family of transcription factors, which contain the TEA/ATTS DNA-binding domain. It is preferentially expressed in the skeletal muscle, and binds to the M-CAT regulatory element found in promoters of muscle-specific genes to direct their gene expression. Alternatively spliced transcripts encoding distinct isoforms, some of which are translated through the use of a non-AUG (UUG) initiation codon, have been described for this gene.

Source: NCBI Gene 7004 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 82 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• Transcription factor: yes — 14 downstream targets (CollecTRI)
• MANE Select transcript: NM_003213

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11717
Approved symbol	TEAD4
Name	TEA domain transcription factor 4
Location	12p13.33
Locus type	gene with protein product
Status	Approved
Aliases	TEF-3, TEFR-1, EFTR-2, RTEF-1
Ensembl gene	ENSG00000197905
Ensembl biotype	protein_coding
OMIM	601714
Entrez	7004

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 nonsense_mediated_decay

ENST00000358409, ENST00000359864, ENST00000397122, ENST00000443986, ENST00000536826, ENST00000540314, ENST00000543035, ENST00000544666

RefSeq mRNA: 3 — MANE Select: NM_003213 NM_003213, NM_201441, NM_201443

CCDS: CCDS31729, CCDS31730, CCDS41737

Canonical transcript exons

ENST00000359864 — 13 exons

Exon	Start	End
ENSE00001276069	3040107	3040259
ENSE00001276077	3037968	3038108
ENSE00001276084	3021844	3022017
ENSE00001276090	3020634	3020773
ENSE00001369261	2959948	2960040
ENSE00001796160	2959397	2959481
ENSE00002224630	2994738	2994992
ENSE00002270937	3040365	3040676
ENSE00003494634	3017398	3017526
ENSE00003589946	3011004	3011068
ENSE00003601570	3019115	3019170
ENSE00003653885	3012170	3012232
ENSE00003785144	3018545	3018588

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 96.21.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.4142 / max 250.6254, expressed in 1534 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
123462	10.0621	1428
123469	3.4893	1241
123460	2.1819	1011
123461	1.6306	835
123463	0.4734	238
123467	0.4030	216
123464	0.3471	172
123459	0.3231	152
123468	0.2518	117
123466	0.1078	34

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
hindlimb stylopod muscle	UBERON:0004252	96.21	gold quality
gastrocnemius	UBERON:0001388	96.03	gold quality
muscle of leg	UBERON:0001383	94.86	gold quality
muscle organ	UBERON:0001630	94.22	gold quality
gluteal muscle	UBERON:0002000	93.57	gold quality
triceps brachii	UBERON:0001509	93.37	gold quality
tibialis anterior	UBERON:0001385	92.82	gold quality
quadriceps femoris	UBERON:0001377	92.58	gold quality
skeletal muscle tissue	UBERON:0001134	92.52	gold quality
vastus lateralis	UBERON:0001379	92.35	gold quality
body of pancreas	UBERON:0001150	91.81	gold quality
biceps brachii	UBERON:0001507	91.47	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.20	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	90.24	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	90.19	gold quality
muscle tissue	UBERON:0002385	90.01	gold quality
diaphragm	UBERON:0001103	89.94	gold quality
deltoid	UBERON:0001476	89.08	gold quality
right lobe of thyroid gland	UBERON:0001119	88.35	gold quality
right lung	UBERON:0002167	88.21	gold quality
left lobe of thyroid gland	UBERON:0001120	87.80	gold quality
upper lobe of left lung	UBERON:0008952	87.79	gold quality
upper lobe of lung	UBERON:0008948	87.19	gold quality
cartilage tissue	UBERON:0002418	87.17	gold quality
pancreas	UBERON:0001264	86.92	gold quality
thyroid gland	UBERON:0002046	86.59	gold quality
tendon of biceps brachii	UBERON:0008188	86.21	gold quality
endometrium epithelium	UBERON:0004811	85.35	gold quality
sural nerve	UBERON:0015488	84.51	gold quality
apex of heart	UBERON:0002098	83.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.12

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

14 targets.

Target	Regulation
ACTA1
ADAM2
CCN2	Unknown
CDX2	Unknown
EIF3K
FGFR1	Activation
HIF1A	Activation
IGFBP1	Activation
MYH7	Activation
PPP1CB	Activation
S100B	Repression
S1PR1	Activation
VEGFA	Repression
VEGFB	Unknown

JASPAR motifs

Motif	Name	Family
MA0809.1	TEAD4	TEF-1-related factors
MA0809.2	TEAD4	TEF-1-related factors
MA0809.3	TEAD4	TEF-1-related factors

JASPAR matrix evidence (PMIDs): PMID:9571041, PMID:23332764

miRNA regulators (miRDB)

13 targeting TEAD4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-3940-5P	99.14	65.26	493
HSA-MIR-4507	99.14	65.27	515
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-629-5P	98.78	68.72	1032
HSA-MIR-6742-3P	97.95	64.50	1490

Literature-anchored findings (GeneRIF, showing 40)

• Constitutive activation of alpha1-adrenergic signaling through the RTEF-1 transcription factor results in chronic elevation of PP1beta expression and connexin dephosphorylation. This mechanism may underlie some defects in cardiac conduction. (PMID:15520314)
• Novel RTEF-1 transcripts are present within human ocular vascular endothelial cells and mouse neural retina during normal and retinopathy of prematurity development, and alternatively spliced products are produced under hyperoxic and hypoxic conditions (PMID:17652751)
• The gain of function studies indicated that TEA domain family member 4 activate NR5A1 gene expression. (PMID:18579725)
• TEF3 mediates the expression of Down syndrome candidate region 1 isoform 1 (DSCR1-1L) in endothelial cells (PMID:18840614)
• the RTEF-1-driven increase of VEGF-B plays an important role in communication between the endothelium and myocardium (PMID:21169295)
• TEF3, mainly its nuclear localization, is required for VEGF-A(165)-induced endothelial proliferation, migration, tube formation, and in vivo Matrigel angiogenesis. (PMID:21169383)
• RTEF-1 as a regulator of HIF-1alpha transcription (PMID:21540178)
• RTEF-1 plays an important role in FGFR1- stimulated vasodilatation. (PMID:22433836)
• Blocking connexin 43 function inhibited RTEF-1-induced endothelial cell connections and aggregation (PMID:22652601)
• High TEAD4 expression is associated with Age-Related Macular Degeneration. (PMID:22761647)
• These results show that RTEF-1-stimulated IGFBP-1 expression may be central to the mechanism by which RTEF-1 attenuates blood glucose levels. (PMID:22843786)
• These data suggest that TFF3 and survivin expressions play a vital role in gastric cancer development, and these two proteins are important markers for prognosis in gastric cancer. (PMID:22996285)
• Data indicate that knockdown of TEAD1/3/4 induces an almost identical cellular senescent phenotype as YAP silencing. (PMID:23576552)
• convergent optimization of the YAP/TAZ TEAD binding site suggests that the similarity in the affinities of binding of YAP to TEAD and of TAZ to TEAD is important for Hippo pathway functionality. (PMID:23780915)
• the multilevel perturbations of TEAD4 at epigenetic, transcriptional and posttranslational levels may contribute to GC development. (PMID:24325916)
• Edg-1 is a potential target gene of RTEF-1 and is involved in RTEF-1-induced angiogenesis in endothelial cells. (PMID:24520353)
• Our findings suggest that genetic variants of Hippo pathway genes, particularly YAP1 rs11225163, TEAD1 rs7944031 and TEAD4 rs1990330, may independently or jointly modulate survival of CM patients. (PMID:25628125)
• the peptides TEF3-11-66 and TEF3-1197-434 functioned as two independent activation domains, suggesting that N-terminal domain of TEF3-1 also has transcriptional activation capacity (PMID:25687649)
• TEAD4 and KLF5, in collaboration, promoted triple negative breast cancer cell proliferation and tumor growth in part by inhibiting p27 gene transcription (PMID:25970772)
• TAZ negatively regulate transcription of DeltaNp63 through TEAD1,2,3 and 4 transcription factors. (PMID:25995450)
• potential anti-oxidation gene and can prevent H2O2-induced endothelial cell oxidative damage by activating Klotho (PMID:26041389)
• The transcription factor TEAD4 regulates a pro-metastasis transcription program in a YAP-independent manner in CRC, thus providing a novel mechanism of TEAD4 transcriptional regulation and its oncogenic role in CRC, independently of the Hippo pathway. (PMID:26387538)
• TEAD4 overexpression induced p16 in HAoSMCs homozygous for the nonrisk coronary disease allele, but not for the risk allele. (PMID:26487755)
• Tead4 cooperates with AP1 transcription factors to coordinate target gene transcription. (PMID:26832411)
• High TEF3 expression is associated with cell cycle progression and angiogenesis in colon cancer. (PMID:26885617)
• TEAD4, the transcription factor that mediates Hippo-YAP signalling, undergoes alternative splicing facilitated by the tumour suppressor RBM4. (PMID:27291620)
• Our results suggest that TEAD4 plays a role in the pathophysiology of atypical teratoid/rhabdoid tumor, which represents a new insight into the biology of this aggressive tumor (PMID:27966820)
• Hippo pathway transcription factor TEAD4 directly associates with the Wnt pathway transcription factor TCF4 via their DNA-binding domains, forming a complex on target genes. VGLL4 binds to this TEAD4-TCF4 complex to inhibit transactivation of both TCF4 and TEAD4. (PMID:28051067)
• Collectively, these results indicate that human papillomavirus 16 E6 induces upregulation of APOBEC3B through increased levels of TEADs, highlighting the importance of the TEAD-APOBEC3B axis in carcinogenesis. (PMID:28077648)
• It was found that the TEAD4-YAP complex in the nuclei may be related closely to transcriptions of G1 arrest-related genes. (PMID:28315328)
• our work provides a structural basis for understanding the regulatory mechanism of TEAD4-mediated gene transcription (PMID:28368398)
• Combining single site-directed mutagenesis and double mutant analyses, the authors conduct a detailed analysis on the role of several residues located at the YAP:TEAD interface. The results provide quantitative understanding of the interactions taking place at the YAP:TEAD interface and give insights into the formation of the YAP:TEAD complex and more particularly on the interaction between TEAD and the ohm-loop found … (PMID:28430104)
• Osmotic stress promotes TEAD4 cytoplasmic translocation via p38 MAPK in a Hippo-independent manner. Stress-induced TEAD inhibition predominates YAP-activating signals and selectively suppresses YAP-driven cancer cell growth. (PMID:28752853)
• TEAD1 and TEAD4 are oncogenic factors, whose aberrant activation are, in part, mediated by the silence of miR-377-3p, miR-1343-3p and miR-4269. (PMID:28759040)
• Studied the effect of TEAD4 acylation on its interaction with YAP and TAZ; found YAP and TAZ bind in a similar manner to both acylated and non-acylated TEAD4. Also found TEAD4 acylation significantly enhances its stability. (PMID:28960584)
• TEAD4 plays an important tumor-promoting role in colorectal cancer by directly targeting the YAP1. (PMID:29157094)
• TEAD4 is up-regulated in lung adenocarcinoma and its expression is an unfavourable prognostic factor.TEAD4 expression is regulated by miR-6839-3p. (PMID:29667772)
• LOX nuclear localization was significantly associated with poor survival in patients with Colorectal cancer (CRC). Nuclear LOX expression was correlated with synchronous or postoperative lung/hepatic metastasis. LOX may prove to be a potential target gene of YAP and TEAD4. (PMID:29766649)
• To analyze the clinical characteristics, treatment methods and prognosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (PMID:30392265)
• High TEAD4 expression is associated with Hepatoblastoma. (PMID:30794805)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tead4	ENSMUSG00000030353
rattus_norvegicus	Tead4	ENSRNOG00000005608
drosophila_melanogaster	sd	FBGN0003345

Paralogs (3): TEAD3 (ENSG00000007866), TEAD2 (ENSG00000074219), TEAD1 (ENSG00000187079)

Protein

Protein identifiers

Transcriptional enhancer factor TEF-3 — Q15561 (reviewed: Q15561)

Alternative names: TEA domain family member 4, Transcription factor 13-like 1, Transcription factor RTEF-1

All UniProt accessions (8): A0A0A0MRF3, Q15561, H0Y7B0, H0YFF9, H0YFK0, H0YG62, H0YGS2, Q53GI4

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor which plays a key role in the Hippo signaling pathway, a pathway involved in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Acts by mediating gene expression of YAP1 and WWTR1/TAZ, thereby regulating cell proliferation, migration and epithelial mesenchymal transition (EMT) induction. Binds specifically and non-cooperatively to the Sph and GT-IIC ’enhansons’ (5’-GTGGAATGT-3’) and activates transcription. Binds to the M-CAT motif.

Subunit / interactions. Interacts with YAP1 and WWTR1/TAZ.

Subcellular location. Nucleus.

Tissue specificity. Preferentially expressed in skeletal muscle. Lower levels in pancreas, placenta, and heart.

Isoforms (3)

UniProt ID	Names	Canonical?
Q15561-1	1	yes
Q15561-2	2
Q15561-3	3

RefSeq proteins (3): NP_003204, NP_958849, NP_958851 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000818	TEA/ATTS_dom	Domain
IPR016361	TEF_metazoa	Family
IPR027255	TEF-3	Family
IPR038096	TEA/ATTS_sf	Homologous_superfamily
IPR041086	YBD	Domain
IPR050937

Pfam: PF01285, PF17725

UniProt features (54 total): strand 16, helix 12, mutagenesis site 11, sequence conflict 5, region of interest 2, compositionally biased region 2, splice variant 2, chain 1, DNA-binding region 1, turn 1, sequence variant 1

Structure

Experimental structures (PDB)

23 structures.

PDB	Method	Resolution (Å)
9SYN	X-RAY DIFFRACTION	1.3
6GEI	X-RAY DIFFRACTION	1.65
6HIK	X-RAY DIFFRACTION	1.65
6SEN	X-RAY DIFFRACTION	1.65
8A8R	X-RAY DIFFRACTION	1.7
6GEC	X-RAY DIFFRACTION	1.7
9QKQ	X-RAY DIFFRACTION	1.74
6GE6	X-RAY DIFFRACTION	1.8
6GE3	X-RAY DIFFRACTION	1.85
5OAQ	X-RAY DIFFRACTION	1.95
6GEE	X-RAY DIFFRACTION	1.96
6GE4	X-RAY DIFFRACTION	1.97
8CAA	X-RAY DIFFRACTION	2
6Q36	X-RAY DIFFRACTION	2.01
6GE5	X-RAY DIFFRACTION	2.05
6Q2X	X-RAY DIFFRACTION	2.1
9SYI	X-RAY DIFFRACTION	2.1
6GEG	X-RAY DIFFRACTION	2.23
8C17	X-RAY DIFFRACTION	2.25
6GEK	X-RAY DIFFRACTION	2.28
6SEO	X-RAY DIFFRACTION	2.55
5GZB	X-RAY DIFFRACTION	2.7
5NO6	X-RAY DIFFRACTION	2.88

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15561-F1	76.75	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (11):

Position	Phenotype
297	important loss of interaction with yap1 and complete loss of transforming ability.
299	important loss of interaction with yap1 and complete loss of transforming ability.
337	reduced interaction with yap1.
373	reduced transforming ability.
380	reduced transforming ability.
391	reduced transforming ability.
393	reduced transforming ability.
427	reduced transforming ability.
429	loss of interaction with yap1 and also activation by yap1.
429	important loss of interaction with yap1 and complete loss of transforming ability.
266	reduced transforming ability.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression
R-HSA-8951671	RUNX3 regulates YAP1-mediated transcription
R-HSA-9796292	Formation of axial mesoderm
R-HSA-9819196	Zygotic genome activation (ZGA)
R-HSA-9909649	Regulation of PD-L1(CD274) transcription
R-HSA-1266738	Developmental Biology
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8878159	Transcriptional regulation by RUNX3
R-HSA-9758941	Gastrulation
R-HSA-9816359	Maternal to zygotic transition (MZT)

MSigDB gene sets: 171 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, MYOGENIN_Q6, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_HIPPO_SIGNALING, GOBP_BLASTOCYST_FORMATION, WEI_MYCN_TARGETS_WITH_E_BOX, DAUER_STAT3_TARGETS_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, WOO_LIVER_CANCER_RECURRENCE_UP, KORKOLA_EMBRYONAL_CARCINOMA_UP, BILD_E2F3_ONCOGENIC_SIGNATURE

GO Biological Process (16): skeletal system development (GO:0001501), cell fate specification (GO:0001708), trophectodermal cell fate commitment (GO:0001830), DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), muscle organ development (GO:0007517), embryo implantation (GO:0007566), hippo signaling (GO:0035329), embryonic organ development (GO:0048568), positive regulation of stem cell population maintenance (GO:1902459), in utero embryonic development (GO:0001701), blastocyst formation (GO:0001825), regulation of DNA-templated transcription (GO:0006355), cell fate commitment (GO:0045165), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA-binding transcription factor activity (GO:0003700), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (6): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737), protein-DNA complex (GO:0032993)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Generic Transcription Pathway	2
Developmental Biology	2
Transcriptional regulation by RUNX3	1
Gastrulation	1
Maternal to zygotic transition (MZT)	1
Regulation of PD-L1(CD274) expression	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
cell fate commitment	2
cellular developmental process	2
transcription by RNA polymerase II	2
animal organ development	2
DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
protein-containing complex	2
system development	1
trophectodermal cell differentiation	1
gene expression	1
RNA biosynthetic process	1
muscle structure development	1
multicellular organism development	1
female pregnancy	1
reproductive process	1
intracellular signal transduction	1
embryo development	1
stem cell population maintenance	1
positive regulation of developmental process	1
positive regulation of multicellular organismal process	1
regulation of stem cell population maintenance	1
chordate embryonic development	1
blastocyst development	1
anatomical structure formation involved in morphogenesis	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cell differentiation	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1

Protein interactions and networks

STRING

2086 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TEAD4	YAP1	P46937	992
TEAD4	MCAT	Q8IVS2	885
TEAD4	VGLL4	Q14135	881
TEAD4	VGLL1	Q99990	879
TEAD4	EP300	Q09472	844
TEAD4	SMAD3	P84022	802
TEAD4	CDX2	Q99626	799
TEAD4	WWTR1	Q9GZV5	786
TEAD4	ELF5	Q9UKW6	734
TEAD4	GATA3	P23771	709
TEAD4	LATS1	O95835	708
TEAD4	POU5F1	P31359	705
TEAD4	EOMES	O95936	663
TEAD4	VGLL3	A8MV65	660
TEAD4	LATS2	Q9NRM7	650

IntAct

181 interactions, top by confidence:

A	B	Type	Score
YAP1	TEAD4	psi-mi:“MI:0915”(physical association)	0.930
TEAD4	YAP1	psi-mi:“MI:0407”(direct interaction)	0.930
TEAD4	YAP1	psi-mi:“MI:0914”(association)	0.930
YAP1	TEAD4	psi-mi:“MI:0407”(direct interaction)	0.930
TEAD4	WWTR1	psi-mi:“MI:0915”(physical association)	0.920
VGLL4	TEAD4	psi-mi:“MI:0407”(direct interaction)	0.760
TEAD4	VGLL4	psi-mi:“MI:0915”(physical association)	0.760
TEAD4	CEP55	psi-mi:“MI:0915”(physical association)	0.740
TEAD4	TRIM27	psi-mi:“MI:0915”(physical association)	0.720
TEAD4	TRAF1	psi-mi:“MI:0915”(physical association)	0.720
TEAD4	KRT40	psi-mi:“MI:0915”(physical association)	0.720
TEAD4	GOLGA2	psi-mi:“MI:0915”(physical association)	0.720
TEAD4	MTUS2	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (165): TEAD4 (Two-hybrid), TEAD4 (Two-hybrid), TEAD4 (Two-hybrid), TRAF1 (Two-hybrid), PNMA1 (Two-hybrid), KIAA0753 (Two-hybrid), CCNDBP1 (Two-hybrid), RABGEF1 (Two-hybrid), CEP55 (Two-hybrid), CEP70 (Two-hybrid), LZTS2 (Two-hybrid), SSX2IP (Two-hybrid), CCDC172 (Two-hybrid), TEAD4 (Affinity Capture-MS), AMOTL1 (Affinity Capture-MS)

ESM2 similar proteins: B5DF93, D2HNW6, O14896, P52633, P56477, P70671, P97431, Q08DD6, Q13568, Q14653, Q15561, Q15562, Q1JPG0, Q3B7M3, Q3TC46, Q3ZBK7, Q4JF28, Q4KLN4, Q53GS7, Q58DJ0, Q5DTY9, Q5R8Q4, Q5RAS2, Q62717, Q68DU8, Q6A0A9, Q6DEZ2, Q6NUQ4, Q7L4E1, Q86TB9, Q86UW7, Q86UW9, Q8AVJ1, Q8BK03, Q8BYR5, Q8CDG3, Q8CF97, Q8CID0, Q8HWS3, Q8IY22

Diamond homologs: A0A0A7HMS2, B6H7F3, C0STD9, E9EMI7, E9RD40, I1S4T3, K9GDC6, P18412, P20945, P28347, P30051, P30052, P48301, P48984, P70210, Q15561, Q15562, Q19849, Q2U9L6, Q5ANJ4, Q62296, Q90701, Q99594, W6PQG8, Q25214

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
WWTR1	up-regulates	TEAD4	binding
YAP1	up-regulates	TEAD4	binding
YAP1	“up-regulates activity”	TEAD4	binding
TEAD4	“up-regulates quantity by expression”	CCN2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3139 predictions. Top by Δscore:

Variant	Effect	Δscore
12:2994988:GTATG:G	donor_gain	1.0000
12:2994990:ATGGT:A	donor_loss	1.0000
12:2994991:TGGT:T	donor_loss	1.0000
12:2994992:GGT:G	donor_loss	1.0000
12:2994993:GT:G	donor_loss	1.0000
12:2994994:T:A	donor_loss	1.0000
12:3011062:G:GT	donor_gain	1.0000
12:3012229:AAAGG:A	donor_loss	1.0000
12:3012231:AGGTA:A	donor_loss	1.0000
12:3012234:T:A	donor_loss	1.0000
12:3014410:G:T	donor_gain	1.0000
12:3017523:AGGGG:A	donor_loss	1.0000
12:3017524:GGG:G	donor_gain	1.0000
12:3017525:GGG:G	donor_gain	1.0000
12:3017527:GTAA:G	donor_loss	1.0000
12:3017528:T:TC	donor_loss	1.0000
12:3018543:A:AG	acceptor_gain	1.0000
12:3018544:G:GG	acceptor_gain	1.0000
12:3018544:GTTTT:G	acceptor_gain	1.0000
12:3018587:GA:G	donor_gain	1.0000
12:3018589:G:GG	donor_gain	1.0000
12:3019113:A:AG	acceptor_gain	1.0000
12:3019114:G:GG	acceptor_gain	1.0000
12:3020632:AG:A	acceptor_gain	1.0000
12:3020633:GG:G	acceptor_gain	1.0000
12:3020633:GGGTT:G	acceptor_gain	1.0000
12:3020772:CGG:C	donor_loss	1.0000
12:3020774:G:GG	donor_gain	1.0000
12:3020775:T:G	donor_loss	1.0000
12:3021826:GACCC:G	acceptor_gain	1.0000

AlphaMissense

2871 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:2994893:T:A	W43R	1.000
12:2994893:T:C	W43R	1.000
12:2994894:G:C	W43S	1.000
12:2994895:G:C	W43C	1.000
12:2994895:G:T	W43C	1.000
12:2994917:T:C	F51L	1.000
12:2994918:T:C	F51S	1.000
12:2994918:T:G	F51C	1.000
12:2994919:C:A	F51L	1.000
12:2994919:C:G	F51L	1.000
12:2994926:G:C	A54P	1.000
12:2994927:C:A	A54D	1.000
12:2994930:T:C	L55P	1.000
12:2994938:T:C	Y58H	1.000
12:2994938:T:G	Y58D	1.000
12:2994947:T:C	C61R	1.000
12:2994948:G:A	C61Y	1.000
12:2994949:T:G	C61W	1.000
12:2994950:G:C	G62R	1.000
12:2994950:G:T	G62C	1.000
12:2994951:G:A	G62D	1.000
12:2994951:G:T	G62V	1.000
12:2994953:A:G	R63G	1.000
12:2994953:A:T	R63W	1.000
12:2994954:G:C	R63T	1.000
12:2994954:G:T	R63M	1.000
12:2994955:G:C	R63S	1.000
12:2994955:G:T	R63S	1.000
12:2994956:C:A	R64S	1.000
12:2994956:C:T	R64C	1.000

dbSNP variants (sampled 300 via entrez): RS1000012605 (12:2999293 C>G,T), RS1000128262 (12:3039217 A>G), RS1000140991 (12:2969344 G>A,T), RS1000142410 (12:3026988 C>T), RS1000148523 (12:2974056 G>A,C), RS1000175200 (12:2957552 C>G,T), RS1000177089 (12:3027193 A>G), RS1000190431 (12:3013297 C>G,T), RS1000205431 (12:2993842 C>A,T), RS1000232996 (12:2988393 C>T), RS1000274526 (12:2968232 A>G,T), RS1000286702 (12:2988669 A>G), RS1000287189 (12:3021606 C>T), RS1000313874 (12:3004237 G>A), RS1000410583 (12:3016162 G>T)

Disease associations

OMIM: gene MIM:601714 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001909_3	Narcolepsy with cataplexy	2.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL4295828 (SINGLE PROTEIN), CHEMBL5465250 (PROTEIN COMPLEX), CHEMBL6066038 (PROTEIN-PROTEIN INTERACTION), CHEMBL6193819 (PROTEIN-PROTEIN INTERACTION), CHEMBL6195574 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 51,894 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL23588	FLUFENAMIC ACID	2	34,797
CHEMBL32350	PIRLINDOLE	2	1,928
CHEMBL63323	NIFLUMIC ACID	2	15,169

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — TEAD (transcriptional enhanced associate domain) transcription factors

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
GNE-7883	Binding	7.52	pIC50

Binding affinities (BindingDB)

104 measured of 110 human assays (110 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
US12083101, Example 71b	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 110	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 112	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 147	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 170	IC50	1 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 12	IC50	1.5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 38	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 56b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 66a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 66b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 67a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 71a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 94a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 99	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 100a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 104b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 108	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 113	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 115a	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 115b	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 121	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 126	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 151	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 152	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 171	IC50	2 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 31	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 33	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 51	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 57b	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 86	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 94b	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 102a	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 120	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 143	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 146	IC50	3 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 8	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 58b	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 69b	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 85a	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 97	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 111	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 140a	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 150	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 164	IC50	4 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 49	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 69a	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 96	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 98	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 103	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
US12083101, Example 141	IC50	5 nM	US-12083101: Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors

ChEMBL bioactivities

121 potent at pChembl≥5 of 177 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.80	Ki	1.6	nM	CHEMBL6147038
8.70	IC50	2	nM	CHEMBL5401444
8.70	IC50	2	nM	CHEMBL5422959
8.70	IC50	2	nM	CHEMBL5400400
8.70	IC50	2	nM	CHEMBL5408536
8.70	IC50	2	nM	CHEMBL5403826
8.52	IC50	3	nM	CHEMBL5419829
8.52	IC50	3	nM	CHEMBL5416415
8.52	IC50	3	nM	CHEMBL5415215
8.52	IC50	3	nM	CHEMBL5438256
8.52	IC50	3	nM	CHEMBL5432828
8.52	IC50	3	nM	CHEMBL5428867
8.05	IC50	9	nM	CHEMBL4567546
8.05	IC50	9	nM	CHEMBL5411200
7.83	Ki	14.9	nM	CHEMBL6142714
7.80	IC50	16	nM	CHEMBL4468725
7.60	Kd	25	nM	CHEMBL4468725
7.35	IC50	45	nM	CHEMBL4467555
7.25	IC50	56	nM	CHEMBL4476332
7.16	IC50	70	nM	CHEMBL242708
7.00	IC50	100	nM	CHEMBL4787565
6.71	IC50	197	nM	CHEMBL4459587
6.70	IC50	200	nM	CHEMBL4776143
6.70	IC50	200	nM	CHEMBL4757924
6.70	IC50	200	nM	CHEMBL4745853
6.70	IC50	200	nM	CHEMBL4757369
6.70	IC50	200	nM	CHEMBL4745831
6.70	IC50	200	nM	CHEMBL242708
6.70	IC50	200	nM	CHEMBL5405832
6.67	IC50	216	nM	CHEMBL4514336
6.52	IC50	300	nM	CHEMBL1701986
6.52	IC50	300	nM	CHEMBL4789889
6.52	IC50	300	nM	CHEMBL4797833
6.52	IC50	300	nM	CHEMBL4750726
6.52	IC50	300	nM	CHEMBL4783341
6.52	IC50	300	nM	CHEMBL4744235
6.52	IC50	300	nM	CHEMBL5405832
6.40	IC50	400	nM	CHEMBL4800702
6.40	IC50	400	nM	CHEMBL4750624
6.40	IC50	400	nM	CHEMBL5424157
6.39	IC50	409	nM	CHEMBL4436894
6.39	IC50	410	nM	CHEMBL5436703
6.30	IC50	500	nM	CHEMBL4757939
6.29	IC50	510	nM	CHEMBL5220985
6.22	IC50	600	nM	CHEMBL5432067
6.17	IC50	672	nM	CHEMBL5397201
6.16	IC50	700	nM	CHEMBL4787565
6.16	IC50	700	nM	CHEMBL5432067
6.10	IC50	800	nM	CHEMBL4763473
6.05	IC50	900	nM	CHEMBL4784286

PubChem BioAssay actives

122 with measured affinity, of 591 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(2S,3S)-5-chloro-6-fluoro-3-methyl-2-(methylaminomethyl)-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-methoxybenzamide	2007263: Inhibition of Avi-His-tagged human TEAD4 (217 to 434 residues)/N-biotinylated-N-terminal Cy5-labelled human YAP (60 to 100 residues) incubated for 1 hr by TR FRET assay	ic50	0.0020	uM
2-[(2S,3S)-2-(aminomethyl)-5-chloro-6-fluoro-3-methyl-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-(2-methoxyethoxy)benzamide	2007263: Inhibition of Avi-His-tagged human TEAD4 (217 to 434 residues)/N-biotinylated-N-terminal Cy5-labelled human YAP (60 to 100 residues) incubated for 1 hr by TR FRET assay	ic50	0.0020	uM
N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-ynamide	2020151: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 0.5 to 4 hrs followed by biotinylated lipid pocket probe addition and measured after 60 min by TR-FRET assay	ic50	0.0020	uM
2-chloro-N-[[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]methyl]prop-2-enamide	2020151: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 0.5 to 4 hrs followed by biotinylated lipid pocket probe addition and measured after 60 min by TR-FRET assay	ic50	0.0020	uM
cyclobuten-1-yl-[3-[9-methyl-6-[4-(trifluoromethoxy)phenyl]purin-2-yl]azetidin-1-yl]methanone	2015512: Displacement of biotinylated lipid pocket probes from His-tagged TEAD4 (unknown origin) preincubated for 4 hrs followed by lipid pocket probe addition and measured after 60 mins by TR-FRET assay	ic50	0.0020	uM
1-[3-[7-[4-(trifluoromethoxy)phenyl]-[1,3]thiazolo[5,4-d]pyrimidin-5-yl]azetidin-1-yl]prop-2-en-1-one	2015512: Displacement of biotinylated lipid pocket probes from His-tagged TEAD4 (unknown origin) preincubated for 4 hrs followed by lipid pocket probe addition and measured after 60 mins by TR-FRET assay	ic50	0.0020	uM
1-[3-[9-methyl-6-[4-(trifluoromethoxy)phenyl]purin-2-yl]azetidin-1-yl]prop-2-en-1-one	2015512: Displacement of biotinylated lipid pocket probes from His-tagged TEAD4 (unknown origin) preincubated for 4 hrs followed by lipid pocket probe addition and measured after 60 mins by TR-FRET assay	ic50	0.0020	uM
2-[(2S,3R)-2-(aminomethyl)-5-chloro-6-fluoro-3-(hydroxymethyl)-2-phenyl-3H-1-benzofuran-4-yl]-3-fluoro-4-methoxybenzamide	2007263: Inhibition of Avi-His-tagged human TEAD4 (217 to 434 residues)/N-biotinylated-N-terminal Cy5-labelled human YAP (60 to 100 residues) incubated for 1 hr by TR FRET assay	ic50	0.0020	uM
2-chloro-N-methyl-N-[[1-[4-(trifluoromethoxy)phenyl]indazol-3-yl]methyl]acetamide	2020151: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 0.5 to 4 hrs followed by biotinylated lipid pocket probe addition and measured after 60 min by TR-FRET assay	ic50	0.0030	uM
(E)-1-[3-[4-chloro-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]-4-hydroxybut-2-en-1-one	2020151: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 0.5 to 4 hrs followed by biotinylated lipid pocket probe addition and measured after 60 min by TR-FRET assay	ic50	0.0030	uM
1-[3-[4-(hydroxymethyl)-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one	2020151: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 0.5 to 4 hrs followed by biotinylated lipid pocket probe addition and measured after 60 min by TR-FRET assay	ic50	0.0030	uM
N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1-benzofuran-5-yl]methyl]ethenesulfonamide	2015512: Displacement of biotinylated lipid pocket probes from His-tagged TEAD4 (unknown origin) preincubated for 4 hrs followed by lipid pocket probe addition and measured after 60 mins by TR-FRET assay	ic50	0.0030	uM
N-[[4-(3-hydroxyprop-1-ynyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide	2015512: Displacement of biotinylated lipid pocket probes from His-tagged TEAD4 (unknown origin) preincubated for 4 hrs followed by lipid pocket probe addition and measured after 60 mins by TR-FRET assay	ic50	0.0030	uM
N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydro-1-benzofuran-5-yl]methyl]-N-methylprop-2-enamide	2015512: Displacement of biotinylated lipid pocket probes from His-tagged TEAD4 (unknown origin) preincubated for 4 hrs followed by lipid pocket probe addition and measured after 60 mins by TR-FRET assay	ic50	0.0030	uM
(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,4R)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[1-[[(2S)-5-carbamimidamido-2-[[(2S)-3-(6-chloro-1H-indol-3-yl)-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]pentanoyl]amino]cyclopropanecarbonyl]amino]pentanoyl]amino]hexanoyl]amino]-3-cyclobutylpropanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-naphthalen-1-ylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carboxylic acid	1634096: Inhibition of human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) interaction with N-biotinylated YAP (60 to 100 residues) incubated for 2 hrs by by TR-FRET assay	ic50	0.0090	uM
1-[3-[4-ethynyl-1-[4-(trifluoromethoxy)phenyl]pyrazolo[3,4-b]pyridin-3-yl]azetidin-1-yl]prop-2-en-1-one	2020151: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 0.5 to 4 hrs followed by biotinylated lipid pocket probe addition and measured after 60 min by TR-FRET assay	ic50	0.0090	uM
(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,4R)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-3-(6-chloro-1H-indol-3-yl)-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-cyclobutylpropanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-naphthalen-1-ylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carboxylic acid	1634096: Inhibition of human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) interaction with N-biotinylated YAP (60 to 100 residues) incubated for 2 hrs by by TR-FRET assay	ic50	0.0160	uM
(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-3-(6-chloro-1H-indol-3-yl)-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-cyclobutylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-naphthalen-1-ylpropanoyl]amino]hexanoyl]amino]-4-carboxybutanoyl]pyrrolidine-2-carboxylic acid	1634096: Inhibition of human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) interaction with N-biotinylated YAP (60 to 100 residues) incubated for 2 hrs by by TR-FRET assay	ic50	0.0450	uM
(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid	1634096: Inhibition of human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) interaction with N-biotinylated YAP (60 to 100 residues) incubated for 2 hrs by by TR-FRET assay	ic50	0.0560	uM
2-[anilino(phenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676394: Binding affinity to nonacylated N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells assessed as inhibition of protein-FAM-YAP (50 to 100 residues) interaction preincubated for 10 mins followed by FAM YAP addition and measured after 1 hr by fluorescence assay	ic50	0.0700	uM
N-[5-cyano-4-[(E)-2-(4,4-difluorocyclohexyl)ethenyl]-2-pyridinyl]prop-2-enamide	2007283: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 30 mins followed by biotinylated lipid pocket addition and measured after 60 mins by TR-FRET assay	ic50	0.1000	uM
N-[7-[(E)-2-(4,4-difluorocyclohexyl)ethenyl]-4-fluoro-2,3-dihydro-1-benzofuran-5-yl]prop-2-enamide	2007283: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 30 mins followed by biotinylated lipid pocket addition and measured after 60 mins by TR-FRET assay	ic50	0.1000	uM
N-[6-methoxy-5-[(E)-2-[4-(trifluoromethyl)cyclohexyl]ethenyl]pyridazin-3-yl]prop-2-enamide	2007283: Inhibition of His-tagged TEAD4 (unknown origin) preincubated for 30 mins followed by biotinylated lipid pocket addition and measured after 60 mins by TR-FRET assay	ic50	0.1000	uM
2-[anilino-(2-fluorophenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.1000	uM
N-[4-(naphthalen-2-ylmethyl)phenyl]ethenesulfonamide	1580415: Inhibition of N-terminal His6 tagged human TEAD4-YBD (217 to 434 residues) expressed in Escherichia coli C43 (DE3) cells assessed as reduction in autopalmitoylation preincubated for 2 hrs followed by palmitoyl alkyne-coenzyme A addition and measured after 30 mins by immunoblot analysis	ic50	0.1970	uM
2-[anilino(naphthalen-2-yl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.2000	uM
2-[(3-fluoroanilino)-phenylmethyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.2000	uM
2-[anilino-(4-bromophenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.2000	uM
2-[anilino-(4-propan-2-ylphenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.2000	uM
2-[anilino-(4-methylphenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.2000	uM
5-methoxy-4-[3-(trifluoromethyl)anilino]-1,3-dihydroisoindole-2-carbonitrile	1964894: Displacement of FAM- labeled YAP1 peptide (60 to 99 residues) from human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) cells incubated for 24 hrs by fluorescence polarization-based competitive binding assay	ic50	0.2000	uM
(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-3-(6-chloro-1H-indol-3-yl)-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]hexanoyl]amino]-3-cyclobutylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-naphthalen-1-ylpropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid	1634096: Inhibition of human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) interaction with N-biotinylated YAP (60 to 100 residues) incubated for 2 hrs by by TR-FRET assay	ic50	0.2160	uM
3-hydroxy-6-(hydroxymethyl)-2-[phenyl-(pyridin-2-ylamino)methyl]pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.3000	uM
4-[[[3-hydroxy-6-(hydroxymethyl)-4-oxopyran-2-yl]-phenylmethyl]amino]benzamide	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.3000	uM
3-hydroxy-6-(hydroxymethyl)-2-[[(4-methyl-2-pyridinyl)amino]-phenylmethyl]pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.3000	uM
2-[anilino-(4-fluorophenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.3000	uM
4-[anilino-[3-hydroxy-6-(hydroxymethyl)-4-oxopyran-2-yl]methyl]benzamide	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.3000	uM
2-[(2-fluorophenyl)-(pyridin-2-ylamino)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.3000	uM
2-[(benzylamino)-phenylmethyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.4000	uM
2-[(4-bromophenyl)-(pyridin-2-ylamino)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.4000	uM
4-[3-(trifluoromethyl)anilino]-1,3,3a,4,5,6,7,7a-octahydroisoindole-2-carbonitrile	1964903: Inhibition of TEAD4 (unknown origin) transfected in human HEK293 cells co-transfected with renilla plasmid assessed as inhibition of transcriptional activity incubated for 24 hrs by dual Glo-luciferase reporter assay	ic50	0.4000	uM
(2S)-1-[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-6-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-3-(6-chloro-1H-indol-3-yl)-2-[[(2S)-pyrrolidine-2-carbonyl]amino]propanoyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]pentanoyl]amino]hexanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-naphthalen-1-ylpropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid	1634096: Inhibition of human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) interaction with N-biotinylated YAP (60 to 100 residues) incubated for 2 hrs by by TR-FRET assay	ic50	0.4090	uM
tert-butyl 4-[[1-(6-chloro-1H-indol-3-yl)-2-oxo-2-[[(1S,2S,4S)-1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl]amino]ethyl]-[[1-[(6-methylimidazo[1,2-a]pyridin-2-yl)methyl]triazol-4-yl]methyl]amino]-4-oxobutanoate	2007261: Inhibition of N-terminal His-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-codonPlus (DE3)-RIPL cells by fluorescence polarisation assay	ic50	0.4100	uM
2-[anilino(pyridin-2-yl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.5000	uM
tert-butyl 4-[[1-(6-chloro-1H-indol-3-yl)-2-oxo-2-[(1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)amino]ethyl]-[[1-[(7-methylimidazo[1,2-a]pyridin-2-yl)methyl]triazol-4-yl]methyl]amino]-4-oxobutanoate	1916164: Inhibition of YAP binding to human TEAD4 by fluorescence polarization assay	ic50	0.5100	uM
5-fluoro-4-[3-(trifluoromethyl)anilino]-1,3-dihydroisoindole-2-carbonitrile	1964894: Displacement of FAM- labeled YAP1 peptide (60 to 99 residues) from human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21 (DE3) cells incubated for 24 hrs by fluorescence polarization-based competitive binding assay	ic50	0.6000	uM
2-chloro-1-[2-[3-(trifluoromethyl)anilino]phenyl]ethanone	1676397: Inhibition of CPM binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by CPM addition and measured after 1 hr by fluorescence assay	ic50	0.8000	uM
2-[1,3-dihydroisoindol-2-yl(phenyl)methyl]-3-hydroxy-6-(hydroxymethyl)pyran-4-one	1676399: Inhibition of FITC-labeled palmitate tracer binding to N-terminal His6-tagged human TEAD4 (217 to 434 residues) expressed in Escherichia coli BL21-CodonPlus (DE3)-RIPL cells preincubated for 10 mins followed by FITC-labeled palmitate tracer addition and measured after 1 hr by fluorescence assay	ic50	0.9000	uM
2-(3-chloro-N-(2-chloroacetyl)anilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide	1977251: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 48 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	0.9000	uM
3-[(2-chloroacetyl)amino]-1-benzofuran-2-carboxamide	1977244: Inhibition of GST-tagged TEAD4 (217 to 434 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells/FAM-labelled YAP1 (60 to 99 residues)(unknown origin) protein-protein interaction preincubated for 24 hrs at 4 degree C with TEAD4 followed by fluorescent labelled YAP1 addition by fluorescence polarization assay	ic50	0.9000	uM

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation	3
sodium arsenite	decreases expression, increases abundance	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
Nickel	increases expression	2
Tobacco Smoke Pollution	increases expression	2
Cyclosporine	decreases expression	2
Cadmium Chloride	decreases expression	2
tert-Butylhydroperoxide	affects expression, decreases expression	2
Particulate Matter	decreases expression, decreases reaction, increases abundance	2
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
arsenite	affects binding, increases reaction	1
zinc chromate	decreases expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation, increases methylation	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
chromium hexavalent ion	decreases expression, increases abundance	1
seocalcitol	decreases expression	1
rofecoxib	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
jinfukang	affects cotreatment, decreases expression	1
incobotulinumtoxinA	decreases expression	1
NSC 689534	affects binding, decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1

ChEMBL screening assays

131 unique, capped per target: 131 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4120896	Binding	Binding affinity to human His-tagged TEAD4 YBD (217 to 434 residues) expressed in Escherichia coli BL21(DE3) after 30 mins by ITC assay	Targeting Transcriptional Enhanced Associate Domains (TEADs). — J Med Chem

Cellosaurus cell lines

8 cell lines: 4 embryonic stem cell, 3 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7F8	SEES3-1V human TEAD4, clone1	Embryonic stem cell	Male
CVCL_A7F9	SEES3-1V human TEAD4, clone2	Embryonic stem cell	Male
CVCL_A7G0	SEES3-1V human TEAD4, clone3	Embryonic stem cell	Male
CVCL_A8RD	WAe001-A-68	Embryonic stem cell	Male
CVCL_B1HX	Abcam A-549 TEAD4 KO	Cancer cell line	Male
CVCL_B3J5	Abcam HEK293T TEAD4 KO	Transformed cell line	Female
CVCL_TR86	HAP1 TEAD4 (-) 1	Cancer cell line	Male
CVCL_XU16	HAP1 TEAD4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.